×
Home
Archive Submission Guidelines
News Contact
Original article
Crossmark

The impact of biological therapy on health-related quality of life in patients with psoriasis

By
Katarina Nikolić ,
Katarina Nikolić

University of Nis , Niš , Serbia

Dragan Jovanović ,
Dragan Jovanović

University of Nis , Niš , Serbia

Lena Stojković
Lena Stojković

Klinički centar Niš , Niš , Serbia

Abstract

Psoriasis is a chronic, relapsing, non-infectious dermatosis, affecting patients' quality of life. There is still insufficient evidence from routine clinical practice on how the biological therapy improves the quality of life of patients with psoriasis. The aim of our study was to examine the effectiveness of biological therapy, regardless of the drug type, on health-related quality of life (HRQoL) in patients with psoriasis. We performed a prospective observational pilot study at the Clinic of Dermatovenerology, University Clinical Center Niš in the period from from October 1, 2019 to March 1, 2020. The study involved 29 patients with psoriasis vulgaris (11 females, 18 males) on biological therapeutics regardless of the type of the drug. The severity of psoriatic lesions and the patient's response to treatment was assessed using the Psoriasis Area and Severity Index (PASI) before the treatment with secukinumab and ustekinumab and after 10 weeks. Dermatology Life Quality Index (DLQI) was determined at the beginning of biological treatment as well as after 10 weeks. The average age of participants was 49.69 ± 12.75 years and the sample consisted mainly of men (62.1%). The average disease duration among men was 16.44 ± 10.05 years, and among women 17.82 ± 12.79 years. The mean DLQI decreased from 15.62 ± 7.79 to 6.34 ± 7.19 after biological treatment. The initial mean PASI and DLQI scores differed significantly from the average control scores (t-test for paired samples, p < 0.0001). Biological therapies of psoriasis, in addition to improving the clinical picture, demonstrated an improvement in the patients' HRQoL very quickly and they should be considered during evaluating the benefits and risks of this type of therapy.

References

1.
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. :m1590.
2.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. The Lancet. 2021;397(10281):1301–15.
3.
Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences. 20(6):1475.
4.
Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. JAMA. 2020;323(19):1945.
5.
Rønholt K, Iversen L. Old and New Biological Therapies for Psoriasis. International Journal of Molecular Sciences. 18(11):2297.

Citation

Article metrics

Google scholar: See link

Citations

Crossref Logo

2

Crossref Logo

Gabrielė Žaliukaitė, Tadas Raudonis

(2026)

The Impact of Biologic Therapy on Quality of Life and Mental Health in Patients with Psoriasis

Journal of Clinical Medicine, 15(11)

10.3390/jcm15114353

Crossref Logo

Florin Ciprian Bujoreanu, Diana Sabina Radaschin, Ana Fulga, Laura Bujoreanu Bezman, Carmen Tiutiuca, Mihaela Crăescu, Carmen Pantiș, Elena Niculet, Alina Pleșea Condratovici, Alin Laurențiu Tatu

(2025)

Cutaneous Changes Beyond Psoriasis: The Impact of Biologic Therapies on Angiomas and Solar Lentigines

Medicina, 61(4)

10.3390/medicina61040565

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.